Method for the enzymatic oxidation of sulfinic acid to sulfonic acid
By using oxidases that generate H2O2 to convert sulfinic acid into sulfonic acid, the problem of low yield and poor economic efficiency of taurine in existing technologies has been solved. This method achieves efficient and economical conversion of sulfinic acid to sulfonic acid, which is suitable for industrial production.
Patent Information
- Application Number
- CN202180054502.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-07-05
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2041-07-05
AI Technical Summary
In existing biotechnological methods, taurine is usually the main product, while taurine is only a byproduct. The production process suffers from low and uneven yields and the use of expensive cofactors NADH or NADPH, resulting in poor economic efficiency.
An enzyme selected from oxidases that produce H2O2 is used to enzymatically oxidize sulfinic acid to sulfonic acid in the presence of a substrate. The conversion of sulfinic acid to sulfonic acid is achieved by using inexpensive substrates and oxidases such as glucose oxidase or alcohol oxidase to generate H2O2.
An economically viable biotechnological method is provided that can efficiently convert sulfinic acid into sulfonic acid, particularly taurine, avoiding chemical steps. This method is suitable for industrial-scale production and meets the needs of the food, animal feed, and pharmaceutical industries.
Smart Images

Figure CN116096909B_ABST
Abstract
Description
[0001] This invention relates to a method for enzymatically oxidizing sulfinic acid of the formula H2N-CH(R)-CH2-SO2H to sulfonic acid of the formula H2N-CH(R)-CH2-SO3H using an enzyme selected from H2O2-producing oxidases, in the presence of the substrate of the enzyme, particularly for enzymatically oxidizing L-cysteine sulfinic acid to L-cysteine sulfonic acid and enzymatically oxidizing taurine to taurine.
[0002] Sulfinates are a class of compounds containing organic bonds between sulfur and oxygen, with the general structure R–S(=O)–OH, where R is an organic group. The parent compound sulfinate has the structure H–S(=O)–OH and is tautomerizable with hyposulfuric acid HO-S-OH. Salts of sulfinates are sulfinates.
[0003] Sulfonic acids are organosulfur compounds with the universal structure R–SO2–OH, where R is an organic group. They each have their own universal structure R–SO2–O. - Salts and esters of R1–SO2–O–R2 (R1 and R2 are organic groups in each case) are called sulfonates (esters).
[0004] It is chemically possible to convert sulfinic acid to sulfonic acid through oxidation, for example, with peroxides (see, for example, Chauvin and Pratt, Angew. Chem. Int. Ed. (2017) 56: 6255-6259). The possible enzymatic oxidation of sulfinic acid to sulfonic acid is insignificant in the chemical industry, but there is great interest in biotechnological methods for producing naturally occurring sulfonic acids from the corresponding sulfinic acids.
[0005] Examples of naturally occurring sulfinic acids include L-cysteine sulfinic acid and taurine. Examples of naturally occurring sulfonic acids include L-cysteine sulfonic acid and taurine.
[0006] Taurine (2-aminoethanesulfonic acid, CAS No. 107-35-7) is an aminosulfonic acid that occurs naturally in nature as a breakdown product of the amino acids cysteine and methionine. Taurine has economic importance; it is used, for example, as an ingredient in energy drinks and in pet food, such as for cats or fish (Salze and Davis, Aquaculture (2015) 437:215-229). However, taurine is also believed to have health-promoting effects (Ripps and Shen, Molecular Vision (2012) 18:2673-2686).
[0007] Currently, commercially available taurine is chemically produced. One known method is the one used at Changshu Yudong Chemical Factory, which starts with ethylene and produces taurine via ethyleneimine. With consumer-driven trends moving away from chemically produced components, biotechnological methods for producing taurine are also receiving increasing attention.
[0008] In nature, taurine exists almost exclusively in the animal kingdom, with only a few instances found in plants, algae, or bacteria. Taurine has multiple biosynthetic pathways (see, for example, the KEGG Pathway Database: "Taurine and hypotaurine metabolism"), particularly starting from L-cysteine. The most important synthetic steps from L-cysteine to taurine are shown in equations (1) through (5).
[0009] (1) L-cysteine + O2 -> L-cysteine sulfinic acid
[0010] (2) L-cysteine sulfinic acid + 1 / 2 O2 -> L-cysteine sulfinic acid
[0011] (3) L-cysteine sulfinic acid -> taurine + CO2
[0012] (4) Taurine + 1 / 2 O2 → Taurine
[0013] (5) L-cysteine → taurine + CO2
[0014] (1) In the first step, L-cysteine is oxidized to L-cysteine sulfinic acid (3-cysteine sulfinic acid, CAS No. 207121-48-0) by the enzyme cysteine dioxygenase (CDO, EC 1.13.11.20).
[0015] (3) and (5): Cysteine sulfinic acid decarboxylase (CSAD, EC 4.1.1.29) decarboxylates L-cysteine sulfinic acid to taurine (2-aminoethanesulfinic acid, CAS No. 300-84-5), and can decarboxylate L-cysteine sulfinic acid to taurine in a similar reaction.
[0016] (2) and (4): The oxidation of cysteine sulfinic acid to cysteine sulfinic acid and the oxidation of taurine sulfinic acid to taurine have not been clearly elucidated.
[0017] One drawback of known biotechnological methods for producing taurine is that taurine is usually the major byproduct. If taurine is desired as the byproduct, a chemical method must be used to oxidize taurine.
[0018] Honjoh et al. (2010), Amino Acids 38:1173-1183, described a genetically engineered yeast strain heterologously expressing the CDO and CSAD genes from carp (Cyprinus carpio). The main product was taurine, with a smaller proportion of taurine. Both products accumulated intracellularly. Therefore, cell disruption was required for product analysis. In the cell extract, for analytical purposes, taurine could be chemically oxidized to taurine by treatment with H2O2. Currently, no method has been described in detail for converting taurine to taurine in a non-chemical step for further use.
[0019] WO 17 / 213142A1 (Ajinomoto) describes a taurine-producing strain obtained by heterologous expression of cysteine dioxygenase and L-cysteine sulfinate decarboxylase in a strain that initially produces cysteine. The major product is taurine, with a maximum yield of 450 μM, which can be converted to taurine in low yields by subsequent chemical treatment with alkali.
[0020] US 2019-0062757 A1 (KnipBio) describes heterologous production strains for the production of taurine or its precursors, wherein the disclosed production strains mostly exhibit uneven product distribution and achieve the highest yield of taurine. Furthermore, the yields obtained are very low, with a maximum of 419 ng / ml of taurine, without any detectable taurine.
[0021] In addition to low yield, existing biotechnological methods for producing taurine also suffer from inconsistent product range, with taurine being the main product and taurine only appearing as a byproduct.
[0022] Veeravalli et al. (2020), bioRxiv Preprint Server doi:https: / / doi.org / 10.1101 / 750273, disclosed a method for the enzymatic oxidation of taurine. They described mammalian flavin-dependent monooxygenase 1 (FMO1) as an enzyme that converts taurine to taurine. The oxidation proceeds according to equation (6):
[0023] (6) Taurine + NAD(P)H + O2 -> Taurine + NAD(P) + H2O
[0024] It is unclear whether the mammalian enzyme FMO1, which is used to convert taurine to taurine according to equation (6), is also applicable to other sulfinic acids with the oxidized form H2N-CH(R)-CH2-SO2H.
[0025] For the oxidation of taurine, FMO1 uses stoichiometric amounts of the cofactor NADH or NADPH. The use of these commercially expensive cofactors makes its technical use uneconomical. Furthermore, for FMO1, which is identified in mammals, there is currently no suitable production method for industrial-scale production. Therefore, there is no economic basis for using the FMO1 enzyme for enzymatic oxidation.
[0026] Therefore, the object of the present invention is to provide an economically advantageous biotechnological method for oxidizing sulfinic acid to sulfonic acid, especially L-cysteine sulfinic acid to L-cysteine sulfonic acid, and taurine to taurine.
[0027] This objective is achieved by a method of enzymatically oxidizing sulfinic acid of the formula H2N-CH(R)-CH2-SO2H to sulfonic acid of the formula H2N-CH(R)-CH2-SO3H using an enzyme selected from H2O2-producing oxidases in the presence of the substrate of said enzyme. Preferably, the method is characterized in that the sulfinic acid is an aminoalkyl sulfinic acid, more preferably 2-aminoalkyl sulfinic acid. Preferably, the method is characterized in that the sulfonic acid is an aminoalkyl sulfonic acid, more preferably 2-aminoalkyl sulfonic acid. More preferably, the sulfinic acid is an aminoalkyl sulfinic acid, and the sulfonic acid is an aminoalkyl sulfonic acid.
[0028] Group R can be any group, and is preferably hydrogen, an organic, straight-chain, branched, cyclic, saturated or unsaturated, aromatic or heteroaromatic group with or without substituents. This means that group R can be substituted or unsubstituted. Preferred substituents are -CN, -NCO, -NR2, -COOH, -COOR, -halogen, -(meth)acryloyl, -epoxy, -SH, -OH, -CONR2, -OR, -CO-R, -COO-R, -OCO-R or -OCOO-R, -SR, -NR-, -N=R, -N=NR or -P=R. It is preferred to use saturated or unsaturated groups having C1-C4 alkyl, more preferably C1-C4 alkyl, vinyl, especially methyl or ethyl, especially methyl. R is preferably selected from R=H or R=CO2H, i.e., preferably, the sulfinic acid is taurine or cysteine sulfinic acid. R=H is particularly preferred.
[0029] Therefore, the present invention also relates to method steps in the biotechnological production of taurine by enzymatic oxidation of L-cysteine sulfinic acid to L-cysteine sulfinic acid and enzymatic catalytic oxidation of taurine sulfinic acid.
[0030] The substrates of enzymes selected from the class of oxidases that produce H2O2 are understood to refer to substances that can be oxidized by the oxidase. Oxidases react with their oxidizable substrates according to formula (7).
[0031] (7) Substrate + O2 → Substrate (ox) +H2O2
[0032] The overall reaction catalyzed by the oxidase that produces H2O2 proceeds according to equation (8):
[0033] (8) Substrate + O2 + H2N-CH(R)-CH2-SO2H->
[0034] Substrate (ox) +H₂O₂ +H₂N-CH(R)-CH₂-SO₂H->
[0035] Substrate (ox) +H2O+H2N-CH(R)-CH2-SO3H
[0036] Suitable H2O2-producing oxidases can be found in the "KEGG Enzymes" database under the search term "oxidases," which is a subset of the enzymes listed there. However, among the many H2O2-producing oxidases, only those that can be industrially utilized are those that produce H2O2 using inexpensive substrates through oxidation according to equation (7).
[0037] Preferred examples of suitable H2O2-producing oxidases (but not limited to) include glucose oxidase (EC 1.1.3.4), hexose oxidase (EC 1.1.3.5), alcohol oxidase (EC 1.1.3.13), secondary alcohol oxidase (EC 1.1.3.18), pyranose oxidase (EC 1.1.3.10), L-lactic acid oxidase (EC 1.1.3.2), aryl alcohol oxidase (EC 1.1.3.7), galactose oxidase (EC 1.1.3.9), L-sorbose oxidase (EC 1.1.3.11), aldehyde oxidase (EC 1.2.3.1), pyruvate oxidase (EC 1.2.3.3 or EC 1.2.3.6), oxalate oxidase (EC 1.2.3.4), and glyoxylate oxidase (EC 1.2.3.4). 1.2.3.5), L-amino acid oxidase (EC 1.4.3.2), D-amino acid oxidase (EC 1.4.3.3 or EC 1.4.3.1), sulfite oxidase (EC 1.8.3.1) and thiol oxidase (EC 1.8.3.2).
[0038] The particularly preferred oxidases for producing H2O2 are glucose oxidase (EC 1.1.3.4), hexose oxidase (EC 1.1.3.5), alcohol oxidase (EC 1.1.3.13), secondary alcohol oxidase (EC 1.1.3.18), pyranose oxidase (EC 1.1.3.10) and L-lactic acid oxidase (EC 1.1.3.2).
[0039] Preferably, the method according to the invention is characterized in that the combination of the oxidase that generates H2O2 and the substrate that it can oxidize is selected from glucose oxidase / glucose, alcohol oxidase / methanol, alcohol oxidase / ethanol, secondary alcohol oxidase / isopropanol and L-lactic acid oxidase / lactic acid.
[0040] In a preferred embodiment, the method is characterized in that the oxidase that produces H2O2 is an alcohol oxidase, and the substrate present is a primary alcohol, more preferably methanol. That is, the oxidase that produces H2O2 is an EC 1.1.3.13 class enzyme of alcohol oxidases as specified in the KEGG database.
[0041] Alcohols are compounds of the general formula R-OH that have one or more hydroxyl groups and do not contain any other functional groups of higher priority. Alcohols are distinguished by the number of carbon and hydrogen atoms on the carbon atom to which the hydroxyl group is also attached. In the case of primary alcohols, two hydrogen atoms are attached to the carbon atom in addition to the carbon atom, giving the general formula RCH2OH. Furthermore, primary alcohols can be converted to aldehydes by oxidation. For example, ethanol becomes the aldehyde, acetaldehyde, by eliminating two hydrogen atoms.
[0042] Preferred primary alcohols include methanol and ethanol, with methanol being a more preferred primary alcohol.
[0043] The R in an alcohol is an alkyl, alkenyl, or alkynyl group, but not an aryl, acyl, or heteroatom group.
[0044] In an alternative preferred embodiment, the method is characterized in that the oxidase that produces H2O2 is glucose oxidase, and the substrate present is glucose. That is, the oxidase that produces H2O2 is an EC 1.1.3.4 class enzyme of glucose oxidase as specified in the KEGG database.
[0045] The prerequisites for industrial implementation of this method are the availability of oxidases that produce H2O2 and inexpensive oxidizable substrates.
[0046] Oxidases that produce H2O2 can be produced, for example, by culturing suitable production strains that naturally produce the relevant oxidases (homological production) or as a result of expressing suitable recombinant gene constructs in a host organism (heterologous production). Furthermore, various H2O2-producing oxidases are commercially available, which positively impacts the economics of the process. Examples of commercially available oxidases include alcohol oxidase AOX from the yeast *Pichia pastoris* (e.g., available from Sigma-Aldrich) or glucose oxidase GOX from the fungus *Aspergillus niger* (from homologous or heterologous production, e.g., available from Sigma-Aldrich). Another example of a commercially available glucose oxidase is marketed under a trade name. (Novozymes) sells enzymes for use in industries such as baking. Preferably, these are oxidases that produce H₂O₂ through fermentation.
[0047] Furthermore, the inexpensive availability of the substrate for the oxidase that produces H2O2 is crucial to the economic feasibility of this method. In the case of AOX alcohol oxidase, the substrate is a primary alcohol, preferably selected from methanol or ethanol. The AOX enzyme produces H2O2 with methanol according to reaction (9):
[0048] (9) Methanol + O2 -> Formaldehyde and H2O2
[0049] In the case of glucose oxidase GOX, the substrate is D-glucose. GOX enzyme reacts with glucose to produce H₂O₂ according to reaction (10):
[0050] (10) D-glucose + O2 -> D-glucose-1,5-lactone + H2O2
[0051] For the purposes of this invention, a method is defined as a multi-stage sequence of working steps, wherein in one or more consecutive reaction batches, reactants (starting materials) are converted into products in a predetermined order via intermediates determined by reaction conditions.
[0052] For the purposes of this invention, a biotechnological method is defined as the production of chemical compounds in industrial applications using enzymes, cells, or whole organisms, such as the production of taurine from taurine using glucose oxidase. In contrast to biotechnological methods, methods characterized by chemical process steps are available.
[0053] A batch or reaction batch is defined as a mixture of reactants (starting materials), enzymes, and optionally other reactants, wherein the reactants are converted into products under defined conditions. The batch or reaction batch of the present invention comprises at least one sulfinic acid of the formula H2N-CH(R)-CH2-SO2H, at least one enzyme selected from oxidases that generate H2O2, a substrate that can be oxidized by the oxidase, and atmospheric oxygen O2.
[0054] Biotransformation refers to the conversion of reactants into products under enzyme catalysis. The method according to the present invention is a biotransformation process.
[0055] The yield of the reaction can be expressed as a volumetric yield (mM or g / L) in terms of the absolute amount of product per unit volume, or as a relative yield of product as a percentage of the reactants used (taking into account the molecular weights of the reactants and products), also known as a yield percentage. In the context of this invention, molar yield as a percentage refers to the total molar amount of sulfonic acid of formula H2N-CH(R)-CH2-SO3H after enzymatic oxidation by an oxidase that produces H2O2 in the presence of its substrate, relative to the sum of the molar amounts of sulfinic acid of formula H2N-CH(R)-CH2-SO2 and sulfonic acid of formula H2N-CH(R)-CH2-SO3H used in the reaction.
[0056] Fermentation is a process step in the production of cell cultures in which a microbial production strain grows under defined conditions of culture medium, temperature, pH, oxygen supply, and medium mixing. Depending on the configuration of the production strain, the aim of fermentation is to produce proteins / enzymes and / or metabolites in the highest possible yield under each condition for further use in the process.
[0057] Enzyme activity is expressed in U / ml, where 1 U / ml is defined as the conversion of 1 μmol substrate / min in a 1 ml test batch under test conditions.
[0058] An open reading frame (ORF, synonym of cds or coding sequence) is a region of DNA or RNA that begins with a start codon and ends with a stop codon, encoding the amino acid sequence of a protein. ORFs are also called coding regions or structural genes.
[0059] A gene or expression unit is a segment of DNA that contains all the essential information for producing biologically active RNA. A gene contains a segment of DNA that produces a single-stranded RNA copy through transcription, along with expression signals that regulate this copying process. Expression signals include, for example, at least one promoter, transcription start point, translation start point, and ribosome binding site. Terminators and one or more operons are additional possible expression signals.
[0060] mRNA, also known as messenger RNA, is a single-stranded ribonucleic acid (RNA) that carries genetic information used to synthesize proteins. mRNA provides the assembly instructions for specific proteins in the cell. The mRNA molecule transmits the information needed for protein synthesis from genetic information (DNA) to the ribosomes responsible for protein synthesis. In the cell, it is transcribed into transcripts of DNA segments corresponding to genes. Through this process, the genetic information stored in the DNA remains unchanged.
[0061] Eukaryotic genes are primarily so-called chimeric genes and, unlike prokaryotic genes, contain non-coding segments called introns (regions within a gene). The coding sequence, called an exon (expression region), is a portion of the eukaryotic gene's DNA that, after being transcribed into RNA, is translated into a protein amino acid sequence via ribosomes. After DNA is transcribed into RNA, introns are spliced out of the original transcript. Protein-coding RNA without introns is called messenger RNA (mRNA) or "mature" mRNA. This undergoes further modifications, such as end-capping and polyadenylation. The coding region of the mature mRNA is then translated into a protein sequence. If a eukaryotic gene containing an exon / intron structure is to be expressed in a prokaryote, it is necessary to reverse-translate the protein sequence or coding region of the mature mRNA into intronless DNA, because exon / intron structure processing does not occur in prokaryotes. When referring to a gene sequence derived from a protein sequence or from mRNA in the context of this invention, it means precisely this reverse translation process. Preferably, sequence optimization, i.e., adapting to the codon usage of the corresponding prokaryote (codon optimization), occurs simultaneously with the reverse translation of the mRNA sequence into the DNA sequence.
[0062] An operon is defined as a higher-level expression unit in which multiple genes are transcribed under the control of a single promoter, but each gene is translated from its own ribosome binding site.
[0063] In the context of this invention, a gene construct is a circular DNA molecule (plasmid, vector) in which at least one gene is linked to other genetic factors (e.g., promoter, ribosome binding site (RBS), terminator, selection marker, origin of replication). The genetic factors of the gene construct exhibit their extrachromosomal inheritance during cell growth and produce proteins encoded by the gene.
[0064] As disclosed in Examples 1 and 2 of the present invention, the combination of H2O2-generating oxidases with their oxidizable substrates is suitable for oxidizing sulfinic acids such as L-cysteine and taurine to the corresponding sulfonic acids L-cysteine and taurine, respectively. This observation is novel and surprising. According to the prior art, although studies have been conducted primarily on an analytical scale (see, for example, Chauvin and Pratt, Angew. Chem. Int. Ed. (2017) 56: 6255-6259), H2O2 is, in principle, suitable for oxidizing sulfinic acids to sulfonic acids. However, for quantitative reactions, H2O2 must be used in at least stoichiometric amounts according to equation (8), which means that a correspondingly large amount of H2O2 is required to produce relatively large amounts of sulfonic acids. Therefore, although H2O2-generating oxidases have been known for a long time, it would not be possible for someone skilled in the art to foresee whether the amount of H2O2 produced by alcohol oxidase reactions or glucose oxidase reactions would be sufficient to oxidize relatively large amounts of sulfinic acids.
[0065] Therefore, the method according to the invention not only has the advantages of a biotechnological method, but also the advantages of being an industrially feasible and economically viable method, as it does not require expensive coenzyme factors.
[0066] As first disclosed in Example 3 and not anticipated from the prior art, the use of glucose oxidase / glucose surprisingly achieved near-quantitative oxidation of taurine to taurine at concentrations associated with chemical synthesis (i.e., 20 g / L). Therefore, the present invention provides a biotechnological method suitable for the sustainable production of sulfonic acids such as taurine for the food, animal feed, or pharmaceutical industries, while avoiding chemical synthesis steps.
[0067] Preferably, the method is characterized in that the sulfinic acid is 2-aminoethanesulfinic acid (taurine), and the sulfonic acid formed is 2-aminoethanesulfonic acid (taurine).
[0068] The enzymatic method for oxidizing sulfinic acid to sulfonic acid according to the present invention is preferably carried out at a temperature of 15°C to 80°C, more preferably 20°C to 60°C, and especially preferably 25°C to 50°C.
[0069] The pH value at which the method according to the invention can be carried out depends on the enzymatic properties of the oxidase that produces H2O2. As described in the examples, the alcohol oxidase reaction is carried out at pH 7.5, and the glucose oxidase reaction is carried out at pH 5.5. The pH range in which the reaction preferably takes place is from pH 3.0 to pH 8.5, more preferably from pH 4.0 to pH 8.0, and particularly preferably from pH 4.5 to pH 7.5.
[0070] The method according to the invention is carried out by passive input (e.g., by mixing reaction batches, for example, on a culture shaker) or by active input (e.g., by introducing compressed air) when atmospheric oxygen is supplied.
[0071] In addition to parameters such as temperature, pH, and oxygen input, the dosage of the oxidase that generates H2O2 in the method according to the invention determines the conversion rate of the reaction and is selected to allow the reaction to proceed with the lowest possible dosage of the oxidase that generates H2O2 in the shortest possible time. The dosage of the oxidase that generates H2O2, such as glucose oxidase, is preferably from 1 U / ml to 200 U / ml, more preferably from 2 U / ml to 150 U / ml, and particularly preferably from 4 U / ml to 100 U / ml.
[0072] In the method according to the invention, the substrate that can be oxidized by the oxidase that generates H2O2 is preferably used in at least an equimolar amount based on the molar content of sulfinic acid (the molar ratio of sulfinic acid to the oxidizable substrate is preferably at least 1:1). Particularly preferred is a molar ratio of sulfinic acid to the oxidizable substrate of at least 1:2, and even more preferred is at least 1:5.
[0073] The reaction time depends on the dose of the oxidase that produces H2O2, and is preferably no more than 72 hours, more preferably no more than 48 hours, and especially preferably no more than 24 hours.
[0074] The solvent used for the reaction is preferably water.
[0075] The concentration of sulfinic acid in this batch is preferably at least 1 g / L, more preferably at least 10 g / L, and especially preferably at least 20 g / L.
[0076] In the biotransformation according to the present invention, the molar conversion rate of sulfinic acid to sulfonic acid is preferably at least 60%, more preferably at least 80%, and particularly preferably at least 90%.
[0077] The method for oxidizing sulfinic acid according to the present invention can be operated in a discontinuous or continuous manner. In discontinuous operation (batch operation), all reactants are added to the batch during the reaction and the batch is post-processed after the reaction is completed.
[0078] In continuous operation, the oxidase is initially loaded into, for example, a membrane reactor or immobilized on a support as a stationary phase, and a substrate containing sulfinic acid and a substrate that can be oxidized by the oxidase to generate H₂O₂ are contacted between the mobile phase and the stationary phase. The contact time between the mobile phase and the stationary phase is preferably set such that the sulfinic acid can react to form a sulfonic acid product.
[0079] Discontinuous (intermittent) operation is preferred.
[0080] The sulfonic acid derived from the enzymatic oxidation according to the invention can be used directly without further post-treatment steps, or it can be enriched or purified by known methods. The degree of enrichment depends on further use.
[0081] In a preferred embodiment, the method is characterized by separating sulfonic acid, more preferably taurine, from the reaction batch.
[0082] Methods for separating sulfonic acids, particularly taurine, are known to those skilled in the art from methods for separating, for example, amino acids. Examples include filtration, centrifugation, extraction, adsorption, ion exchange chromatography, precipitation, and crystallization.
[0083] The method according to the present invention discloses a new and unexpected pathway for the enzymatic oxidation of sulfinic acid to the corresponding sulfonic acid, and is particularly suitable for the biotechnological production of L-cysteine and taurine.
[0084] In the method according to the invention, the progress of the reaction is monitored by measuring the contents of sulfinic acid (reactant) and sulfonic acid (product) at the start of the reaction, at different times during the reaction, and at the end of the reaction. The content of sulfinic acid of formula H2N-CH(R)-CH2-SO2H in solution or cell culture, for example, the content of taurine, or the content of sulfonic acid of formula H2N-CH(R)-CH2-SO3H, for example, the content of taurine, can be determined as follows:
[0085] The content can be quantified directly from aliquots of the batch, provided that the concentration of the sulfinic acid reactant at the start of the reaction is at least 0.1 g / L, equivalent to the equivalent concentration of the sulfonic acid product at the end of a fully converted reaction (e.g., determined by HPLC). This is done by taking 1 ml of the batch aliquot, incubating it at 80°C for 5 minutes, then removing all solids, for example by centrifuging at maximum speed for 5 minutes in a benchtop centrifuge, and quantifying the supernatant by HPLC calibrated for the relevant sulfinic acid or sulfonic acid (as described, for example, in Example 1 for taurine and taurine). If the concentration of the sulfinic acid reactant at the start of the reaction is less than 0.1 g / L, the sample can be pre-concentrated to increase the accuracy of the measurement of the sulfinic acid reactant and sulfonic acid product, for example by evaporating the sample and redissolving it in an appropriate volume of H2O (e.g., 10% of the sample volume, equivalent to a 10-fold concentration).
[0086] If a culture medium containing sulfinic acid is used in the method according to the invention, it can be used for quantification as is. Alternatively, cells can be removed from the culture medium first, for example by centrifugation or filtration, and the resulting cell culture supernatant containing sulfinic acid can be used in the method according to the invention. Sulfinic acid can also be separated from the cell culture supernatant by methods known per se, and the purified sulfinic acid can be used in the method according to the invention.
[0087] The following biotransformation experiments can be used to demonstrate the method according to the present invention and to determine the conversion rate:
[0088] A solution or culture containing sulfinic acid, such as a culture medium containing taurine, preferably fermentation broth, or a corresponding cell culture supernatant, or purified or commercially available sulfinic acid, such as taurine, is used to produce a biotransformation batch. The laboratory-scale biotransformation batch has a batch volume of 10 ml and contains at least 0.1 g / L of sulfinic acid (as described above, from the culture / culture medium / fermentation broth, from centrifuged culture supernatant, or in the form of purified material, and correspondingly quantitatively or in the form of a correspondingly metered commercially available product). Depending on the production scale, the batch volume can also be higher, and for example, at least 1 L on a preparative scale. An oxidase that generates H₂O₂, preferably AOX or GOX, and a substrate that can be oxidized by the oxidase are added, such that the enzyme activity is at least 1 U / ml. When using AOX, at least 1% (v / v) of methanol (i.e., at least 0.1 ml / 10 ml of reaction batch) is added as the substrate for the AOX enzyme. As a substrate for the GOX enzyme, glucose is added to the reaction batch at a dose of at least 10 g / L. Atmospheric oxygen is supplied to the biotransformation batch passively, for example, by mixing on a shaker or using a stirrer (in which case air is allowed), or actively by introducing compressed air or pure oxygen, with or without mixing. When using AOX, the reaction pH is 7.5. When using GOX, the reaction pH is 5.5. For example, the pH of the batch can be kept constant (“pH stat” method) by equipping the batch with a pH electrode connected to a pH control unit, which metered the corrector (base or acid) from a burette. The reaction temperature is 25°C (AOX) or 30°C (GOX). The progress of the reaction can be monitored by the consumption of the reactant taurine and the formation of the product taurine, which can be quantitatively determined, for example, by HPLC. The reaction termination time is selected based on the progress of the reaction. The selected reaction is preferably terminated when the molar yield of sulfonic acid (e.g., taurine) of the formula H2N-CH(R)-CH2-SO3H is at least 60%, more preferably at least 80%, and particularly preferably at least 90%. The sulfonic acid of the formula H2N-CH(R)-CH2-SO3H formed in the reaction batch can then be used for further applications.
[0089] Sulinate can be derived from chemical or fermentation production, preferably the sulfinate used in the method according to the invention is derived from fermentation production. More preferably, the method is characterized in that the sulfinate is taurine and it is derived from fermentation production. When a sulfinate of the formula H2N-CH(R)-CH2-SO2H, such as taurine, is derived from fermentation production and is used in the method according to the invention to form a sulfonic acid of the formula H2N-CH(R)-CH2-SO3H, such as taurine, the main advantage is that the invention provides a biotechnological method for producing a sulfonic acid of the formula H2N-CH(R)-CH2-SO3H, such as taurine. This method does not involve any chemical reaction steps.
[0090] Suitable bacteria strains (e.g., Escherichia coli, Corynebacterium glutamicum, Pantoea ananatis, Bacillus subtilis), algae (e.g., Chlamydomonas reinhardtii), yeasts (e.g., Saccharomyces cerevisiae, Yarrowia lipolytica), or fungi (e.g., Aspergillus niger) are suitable for producing sulfinic acids, such as taurine, which have the formula H2N-CH(R)-CH2-SO2H.
[0091] When the sulfinic acid of the formula H2N-CH(R)-CH2-SO2H is taurine, a microbial strain suitable for taurine production is used. A microbial strain suitable for taurine production is characterized by containing a metabolic pathway leading to taurine according to one of the metabolic pathways specified in the KEGG pathway database “Taurine and Taurine Metabolism.” Since the biosynthesis of taurine according to equations (1) and (3) begins with L-cysteine, a microbial strain also suitable for cysteine production is preferred. As described, for example, in Wada and Takagi, Appl. Microbiol. Biotechnol. (2006) 73:48-54, cysteine production in wild-type microorganisms is closely regulated, meaning that microbial strains with regulated cysteine biosynthesis pathways as described in the prior art are not suitable for producing commercially viable quantities of taurine. Therefore, a microbial strain suitable for taurine production, having a deregulated cysteine biosynthesis pathway, is preferred.
[0092] Microbial strains possessing a deregulated cysteine biosynthetic pathway and thus adapted for cysteine production are characterized by exhibiting at least one of the following modifications:
[0093] a) The microbial strain possesses a modified serA gene encoding 3-phosphoglycerate dehydrogenase (serA), wherein feedback inhibition of L-serine is reduced by at least two-fold relative to the corresponding wild-type enzyme (as described, for example, in EP 1 950287 B1), wherein the SerA enzyme activity can be determined spectrophotometrically, for example, by oxidation of NADH dependent on the SerA substrate 3-phosphohydroxypyruvate, as described, for example, in McCitrick and Pizer, J. Bacteriol. (1980) 141:235-245.
[0094] In a particularly preferred variant of 3-phosphoglycerate dehydrogenase (serA), feedback inhibition of L-serine is reduced by at least 5-fold, particularly preferably by at least 10-fold, and in a more preferred embodiment by at least 50-fold.
[0095] and / or
[0096] b) The microbial strain contains a modified cysE gene encoding a serine-O-acetyl-transferase (cysE), wherein feedback inhibition by cysteine is reduced by at least two-fold relative to the corresponding wild-type enzyme (as described in EP 0858 510B1 or Nakamori et al., Appl. Env. Microbiol. (1998) 64:1607-1611), wherein CysE enzyme activity can be determined spectrophotometrically, for example, by the consumption of the CysE substrate acetyl-CoA caused by the reaction with L-serine to generate O-acetyl-L-serine, as described, for example, Nakamori et al., Appl. Env. Microbiol. (1998) 64:1607-1611. In a particularly preferred variant of the serine O-acetyl-transferase (cysE), feedback inhibition by cysteine is reduced by at least 5-fold, particularly preferably by at least 10-fold, and in a more preferred embodiment by at least 50-fold relative to the corresponding wild-type enzyme.
[0097] and / or
[0098] c) In microbial strains, cysteine export from cells is the result of an overexpression of efflux genes that is at least two-fold greater than that of the corresponding wild-type cells. Cysteine export can be determined by photometric measurements of extracellular cysteine content (including cysteine, cystine, and the adduct (R)-2-methylthiazolidin-2,4-dicarboxylic acid formed by cysteine and pyruvate) as described, for example, in EP 0 885 962 B1.
[0099] Overexpression of efflux genes results in an increase in cysteine exported from the cell relative to wild-type cells, preferably at least 5-fold, more preferably at least 10-fold, and especially preferably at least 20-fold.
[0100] Efflux genes are preferably derived from Escherichia coli ydeD (see EP 0 885 962 B1), yfiK (see EP 1382684B1), cydDC (see WO 2004 / 113373A1), bcr (see US 2005-221453 AA) and emrAB (see US 2005-221453 AA) or corresponding homologous genes from different microorganisms.
[0101] According to existing technology, fermentation is preferred, where a suitable microbial strain for taurine production is used to produce taurine. A culture medium containing taurine, preferably a fermentation broth, is formed. If taurine and taurine are present as byproducts, their content can be quantified from the culture medium. This is done by taking 1 ml of cell density OD... 600 The culture medium was at least 1.0 / ml, incubated at 80°C for 5 minutes, and then all solid components were removed, for example by centrifuging at maximum speed for 5 minutes in a benchtop centrifuge, and the supernatant was quantified by HPLC calibrated for taurine and taurine (as described, for example, in Example 1 for taurine and taurine).
[0102] Those skilled in the art can use isotope analysis to determine whether a substance, such as taurine, which he / she wishes to use as a sulfinic acid in this method is derived from chemical or fermentation production. One distinguishing isotope analysis method is described, for example, in Sieper et al., Rapid Commun. Mass Spectrom. (2006) 20:2521-2527, and is based on the determination of, for example, the isotopic ratio of carbon or nitrogen, which varies depending on whether the product is derived from chemical (petroleum-based) or natural (plant-based) production. The method for producing taurine described in Example 5 is considered a natural (plant-based) production method because the glucose used to cultivate the production strain is derived from plant-based production according to prior art.
[0103] Homologous genes, proteins, or homologous sequences should be understood to mean that the DNA sequence or amino acid sequence, DNA fragment, or protein of the said gene is at least 70% identical, preferably at least 80% identical, and more preferably at least 90% identical.
[0104] DNA identity is determined using the "nucleotide blast" program, which can be found at http: / / blast.ncbi.nlm.nih.gov / and is based on the blastn algorithm. Default parameters are used for the algorithm when aligning two or more nucleotide sequences. The default general parameters are: Maximum target sequence = 100; Short query = "Auto-adjustment parameters for short input sequences"; Expected threshold = 10; Word length = 28; Auto-adjustment parameters for short input sequences = 0. The corresponding default scoring parameters are: Match / mismatch score = 1, -2; Gap Costs = Linear.
[0105] Protein sequences are aligned using the “Protein BLAST” program available at http: / / blast.ncbi.nlm.nih.gov / . This program uses the BLASTP algorithm. Default parameters are used for the algorithm when aligning two or more protein sequences. Default general parameters are: Maximum target sequence = 100; Short query = “Auto-adjustment parameters for short input sequences”; Expected threshold = 10; Word length = 3; Auto-adjustment parameters for short input sequences = 0. Default scoring parameters are: Matrix = BLOSUM62; Void penalty = Existence: 11 Extension: 1; Composition adjustment: Conditional composition score matrix adjustment.
[0106] In a preferred embodiment, the method is characterized in that the sulfinic acid is taurine, and that the taurine is derived from bacterial production, i.e., it is produced using a bacterial production strain. The bacterial production strain is preferably a strain of the Escherichia coli species.
[0107] Preferred bacterial production strains also possess characteristics suitable for cysteine production. Suitable and preferred strains for cysteine production are the *E. coli* K12 W3110 x pCys and *E. coli* K12 W3110-ppsA-MHI x pCys strains disclosed in the examples. As disclosed in Example 5 of the present invention, heterologous expression of the CDO gene encoding cysteine dioxygenase and the CSAD gene encoding cysteine sulfinate decarboxylase in strains W3110 x pCys-CDOrn-CSADhs derived from W3110 x pCys and strain W3110 x pCys-CDOrn-CSADhs derived from W3110-ppsA-MHI x pCys results in the production of taurine and only a small amount of taurine.
[0108] The microbial strain named ppsA-MHI is characterized by the absence of the coding sequence of the Wt-ppsA gene, which has been replaced by ppsA-MHI cds, SEQ ID NO:9, which encodes a protein with the amino acid sequence SEQ ID NO:10.
[0109] ppsA refers to the gene encoding a protein with enzymatic activity of the enzyme class designated EC 2.7.9.2 in the KEGG database. The corresponding protein is also known as PpsA or phosphoenolpyruvate synthase (PEP synthase), or synonymously, phosphoenolpyruvate-H2O kinase. Enzymes are defined as those capable of producing pyruvate from phosphoenolpyruvate in a reversible reaction according to the following formula:
[0110] (11) Phosphoenolpyruvate + Phosphate + AMP <-> Pyruvate + H2O + ATP
[0111] As disclosed in Example 6, by using glucose oxidase and D-glucose, taurine from these batches can be completely converted to taurine in a manner previously unknown. Therefore, the method according to the invention allows for the biotechnological production of taurine by combining the biosynthetic production of taurine with its enzymatic oxidation to taurine.
[0112] In the development and simplification of this method, it is also conceivable to express H2O2-producing oxidases in taurine-producing strains. Suitable genes for H2O2-producing oxidases can be identified in databases such as NCBI (National Center for Biotechnology Information). An example of heterologous glucose oxidase produced in *E. coli* is the GOX gene from *Penicillium amagasakiense* (Witt et al., *App. Environ. Microbiol* (1998) 64:1405-1411).
[0113] A preferred biotechnological method for producing taurine is described, wherein, in a first step, iminotaurine is produced by culturing a production strain, and in a second step, the formed iminotaurine is enzymatically oxidized to taurine without further treatment, particularly preferably by enzymatic oxidation of iminotaurine to taurine using glucose oxidase / D-glucose. In embodiments of the present invention, the biotechnological production of iminotaurine (Example 5) and its enzymatic oxidation to taurine (Example 6) are disclosed.
[0114] In a preferred embodiment, the method is characterized in that the sulfinic acid is taurine, and that the taurine is derived from bacterial production, specifically using a bacterial strain with a deregulated cysteine biosynthesis pathway. A microbial strain with a deregulated cysteine biosynthesis pathway meets the definition described above.
[0115] More preferably, cysteine is first produced, which is further reacted into cysteine sulfinic acid by CDO enzyme present in the production strain according to equation (1) (CDO reaction), and further reacted into taurine by CSAD enzyme also present in the production strain according to equation (3) (CSAD reaction).
[0116] Particularly preferably, the method is characterized in that the sulfinic acid is taurine produced by a bacterial production strain, and the production strain is one of the strains *Escherichia coli* K12 W3110 x pCYS-CDOrn-CSADhs or *Escherichia coli* K12 W3110-ppsA-MHI x pCYS-CDOrn-CSADhs, more preferably *Escherichia coli* K12 W3110-ppsA-MHI x pCYS-CDOrn-CSADhs.
[0117] Therefore, this invention also demonstrates a production strain for the biotechnological production of taurine. Particularly preferred starting strains are *Escherichia coli* K12W3110 x pCys or *Escherichia coli* 12W3110-ppsA-MHIx pCys, suitable for cysteine production. As described in Example 4 of this invention, the vector pCys ( Figure 1 The gene for cysteine dioxygenase (SEQ ID NO:1, encoding a protein with the amino acid sequence SEQ ID NO:2) from *Rattus norvegicus* (CDorn) and the gene for L-cysteine sulfinate decarboxylase (SEQ ID NO:3, nt 1 to nt1509, encoding a protein with the amino acid sequence SEQ ID NO:4) from *Homo sapiens* (CSADhs) were expanded. This produced the vector pCys-CDOrn-CSADhs, suitable for taurine production. Figure 2 ).
[0118] The CDO genes used here are not limited to the brown rat species. Any CDO gene suitable for oxidizing L-cysteine to L-cysteine sulfinic acid is appropriate, according to equation (1) mRNA-derived gene products (proteins). For example, such proteins can be found in the NCBI database by searching for CDO proteins in the "proteins" sub-database using the search term "cysteine dioxygenase". Other CDO proteins known from the prior art, but not limited to, are preferably CDO proteins from Homo sapiens (humans), carp, or Synechococcus (algae) or proteins with 70% homology to their amino acid sequences, more preferably proteins with 80% homology to their amino acid sequences, and particularly preferably, CDO proteins have the amino acid sequence specified in SEQ ID NO:2 and are encoded by the DNA sequence specified in SEQ ID NO:1.
[0119] Similarly, the CSAD gene used is not limited to Homo sapiens species. Any CSAD gene suitable for decarboxylating L-cysteine sulfinic acid to taurine is appropriate, according to equation (3). For example, such proteins can be found in the NCBI database by searching for CSAD proteins in the "proteins" sub-database using the search term "cysteine sulfinic acid decarboxylase". Other CSAD proteins known from the prior art, but not limited to, are preferably CDO proteins or proteins with 70% homology to the amino acid sequence of brown rats, carp, Synechococcus (algae), or Escherichia coli, more preferably proteins with 80% homology to the amino acid sequence, and particularly preferably, the amino acid sequence of the CSAD protein has the sequence specified in SEQ ID NO:4 and is encoded by the DNA sequence specified in nt 1-1509 of SEQ ID NO:3.
[0120] Gene constructs containing the CDO and CSAD genes, such as the particularly preferred construct pCys-CDOrn-CSADhs, can be produced using recombinant DNA techniques known to those skilled in the art, as described in detail in Example 4.
[0121] This is achieved by cloning the CDO gene, which encodes cysteine dioxygenase, and the CSAD gene, which encodes cysteine sulfinate decarboxylase, into a vector suitable for this purpose. In principle, any vector in which the CDO and CSAD genes can be expressed in the production strain is suitable.
[0122] To generate gene constructs containing the CDO and CSAD genes, the CDO and CSAD genes can be cloned separately into vectors as individual expression units, each with its own promoter and optional terminator, or expressed as operons with any desired sequence under the control of a single promoter. Another possibility is an operon structure where the CDO and CSAD genes (each with its own ribosome binding site) are cloned after one of the genes already present in the vector and expressed under the control of the promoter of the relevant gene. Furthermore, all other possible combinations of expression under their own promoters and as operons are possible for the CDO and CSAD genes.
[0123] It is also possible to consider cloning the CDO and CSAD genes as separate expression units independent of the vector into separate vectors (which ensure dysregulated cysteine biosynthesis, such as pCys), or integrating them into the genome of a host organism such as Escherichia coli.
[0124] The preferred form of expression for CDO and CSAD genes is an artificial operon form that has its own ribosome binding site (RBS) in each case, but no promoter of its own.
[0125] Particularly preferably, the vector is pCys-CDOrn-CSADhs, wherein the CDO and CSAD genes are cloned after the serA317 gene present in pCys, such that their expression is controlled by the serA317 promoter according to the following expression unit sequence: serA promoter -> (serA317-cds) -> RBS-(CDOrn-cds) -> RBS-(CSADhs-cds) -> rrnB terminator. The expression unit can also be configured such that the CSAD cds are arranged before the CDO cds.
[0126] pCys-CDOrn-CSADhs possesses additional characteristics that ensure deregulated cysteine biosynthesis through expression units comprising a feedback-resistant variant of 3-phosphoglycerate dehydrogenase, serA317 (serA gene), a feedback-resistant variant of serine O-acetyltransferase, CysEX (cysE gene), and a cysteine efflux protein, ydeD gene. The present invention relates to vectors containing at least one, preferably two, more preferably three genes, serA317, cysEX, and ydeD, wherein the relevant genes may be present in the vector in any desired selection and order.
[0127] Once CDO and CSAD are cloned into the vector, they are then transformed into a suitable host strain in a known manner. A suitable host strain is any microorganism for which recombinant DNA technology is available and which is suitable for the fermentation production of recombinant proteins. Preferred host strains are strains of the *Escherichia coli* species, more preferably *Escherichia coli* K12 W3110 or *Escherichia coli* K12W3110-ppsA-MHI. Strains obtained from the transformation, such as particularly preferred W3110 x pCys-CDOrn-CSADhs or W3110-ppsA-MHI x pCys-CDOrn-CSADhs, are suitable for the production of taurine, as described in Example 5.
[0128] The production of taurine acid using a particularly preferred strain of Escherichia coli K12 W3110 x pCys-CDOrn-CSADhs or Escherichia coli K12W3110-ppsA-MHI x pCys-CDOrn-CSADhs can be achieved by culturing in shake flasks (as described in Example 5) or by fermentation of the strain on a production scale.
[0129] In the method according to the invention, the formed taurine is converted to taurine by enzymatic oxidation. This is accomplished by culturing a cell culture containing taurine with an H2O2-generating oxidase (e.g., glucose oxidase in the presence of glucose) in the presence of a substrate of an H2O2-generating oxidase (see Example 6).
[0130] In a preferred embodiment, the method is characterized in that the sulfinic acid is cysteine sulfinic acid, and the sulfonic acid formed is cysteine sulfonic acid.
[0131] Preferably, the method is characterized in that, based on the molar concentrations of sulfinic acid of formula H2N-CH(R)-CH2-SO2H and sulfonic acid of formula H2N-CH(R)-CH2-SO3H, the molar yield of sulfonic acid of formula H2N-CH(R)-CH2-SO3H is at least 60%, more preferably at least 80%, and especially at least 90%. The amount of sulfinic acid used is preferably at least 1 mM (109.2 mg / L), more preferably at least 10 mM (1.1 g / L), and particularly preferably at least 100 mM (10.9 g / L).
[0132] To determine the molar yield, the molar contents of sulfinic acid and sulfonic acid used in the enzymatic oxidation were determined by HPLC at the start and end of the reaction, as known in the prior art. For example, based on the molecular weight of 109.2 g / mol for taurine and 125.2 g / mol for taurine, the determination can be performed as described in Example 1. The molar content of sulfonic acid in the batch at the end of the reaction relative to the total molar content of sulfinic acid and sulfonic acid at the start of the reaction gives the molar yield of sulfonic acid, expressed as a percentage.
[0133] The accompanying figure shows the plasmids used in the examples.
[0134] Figure 1 :pCys.
[0135] Figure 2 :pCys-CDOrn-CSADhs.
[0136] Figure 3 :pKD46.
[0137] Figure 4 :pKan-SacB.
[0138] Abbreviations used in the diagram:
[0139] bla: Gene conferring ampicillin resistance (β-lactamase)
[0140] kanR: Gene that confers kanamycin resistance
[0141] araC: araC gene (repressor gene)
[0142] ParaC: The promoter of the araC gene
[0143] ParaB: The promoter of the araB gene
[0144] Gam: λ phage Gam recombinant gene
[0145] Bet: λ phage Bet recombinant gene
[0146] Exo: λ phage Exo recombinant gene
[0147] ORI101: Temperature-sensitive origin of replication
[0148] RepA: Gene for plasmid replication protein A
[0149] sacB: Fructan sucrase gene
[0150] pr-f: Primer binding site f (forward)
[0151] pr-r: Primer binding site r (reverse)
[0152] OriC: Replication origin C
[0153] TetR: Gene that confers tetracycline resistance
[0154] P15A ORI: Origin of Replication
[0155] serA317: serA (gene encoding 3-phosphoglycerate dehydrogenase with amino acids 1 to 317) cds
[0156] cysE X: cysE (serine O-acetyltransferase gene, feedback resistance) cds
[0157] ORF306: ydeD (cysteine efflux gene) cds
[0158] ScaI: The cleavage site of the restriction enzyme ScaI
[0159] PpuMI: The cleavage site of the restriction enzyme PpuMI
[0160] CDOrn: CDO (cysteine dioxygenase) in brown rats (cds)
[0161] CSADhs: CSAD (cysteine decarboxylase) is a type of human CDS.
[0162] RBS: Ribosome binding site
[0163] The following examples are provided to further illustrate the invention but are not intended to limit it. Example
[0164] Example 1: Oxidation of taurine and cysteine sulfinic acid using alcohol oxidase (AOX)
[0165] A) Oxidating cysteine sulfinic acid to cysteine sulfonic acid using AOX:
[0166] The reaction was studied in two parallel batches (i.e., with and without AOX). 12 mg of L-cysteine sulfinic acid monohydrate (Sigma-Aldrich) was weighed into each of two 100 mL Erlenmeyer flasks; it was dissolved in 9.9 mL of 100 mM sodium phosphate at pH 7.5, and 0.1 mL of methanol was added (final concentration 1% v / v). To initiate the reaction, 30 μl of a commercially available solution of AOX from Pichia pastoris (Sigma-Aldrich) in 100 mM sodium phosphate at pH 7.5 was added to one batch. According to the manufacturer's information regarding enzyme activity, the AOX activity in this batch was 5 U / mL. A second batch (control batch) without AOX was treated with 30 μl of 100 mM sodium phosphate at pH 7.5. Each batch was shaken at 25 °C and 140 rpm (Infors culture shaker). At the start of the reaction and 5 hours after the start of the reaction, 1 ml was taken from each batch, incubated at 80°C for 5 minutes, and centrifuged at 13,000 rpm for 5 minutes (Heraeus). TM Fresco TM 21 centrifuges were used, and the supernatant was analyzed by HPLC. The contents of L-cysteine and L-cysteine in batches using AOX and batches not using AOX at the start (0 hours) and after 5 hours of reaction time are summarized in Table 1.
[0167] Table 1: Time-varying process of L-cysteine sulfinic acid to L-cysteine sulfonic acid via AOX in the presence of methanol.
[0168]
[0169] B) Oxidize taurine with AOX to taurine:
[0170] The reaction was studied in two parallel batches (i.e., with and without AOX). 12 mg of taurine (Sigma-Aldrich) was weighed into each of two 100 mL Erlenmeyer flasks; it was dissolved in 9.9 mL of 100 mM sodium phosphate at pH 7.5, and 0.1 mL of methanol was added (final concentration 1% v / v). To initiate the reaction, 30 μl of a commercially available solution of AOX from Pichia pastoris (Sigma-Aldrich) in 100 mM sodium phosphate at pH 7.5 was added to one batch. According to the manufacturer's information regarding enzyme activity, the AOX activity in this batch was 5 U / mL. The batch without AOX (control batch) was treated with 30 μl of 100 mM sodium phosphate at pH 7.5. Each batch was shaken at 25 °C and 140 rpm (Infors culture shaker). At the start of the reaction and 5 hours after the start of the reaction, 1 ml was taken from each batch, incubated at 80°C for 5 minutes, and centrifuged at 13,000 rpm for 5 minutes (Heraeus). TM Fresco TM 21 centrifuges were used, and the supernatant was analyzed by HPLC. The contents of taurine and taurine in the batches using alcohol oxidase (AOX) and the batches not using alcohol oxidase at the beginning (0 hours) and after 5 hours of reaction time are summarized in Table 2.
[0171] Table 2: Time-varying process of taurine to taurine via AOX in the presence of methanol.
[0172]
[0173] HPLC analysis of L-cysteine sulfinic acid, L-cysteine sulfinic acid, taurine and taurine:
[0174] To quantify the compounds analyzed in the examples, HPLC methods calibrated separately for L-cysteine sulfinic acid, L-cysteine sulfonic acid, taurine, and taurine were used; all reference materials used for calibration were commercially available (Sigma-Aldrich). An Agilent 1260 Infinity II HPLC system, equipped with a device from the same manufacturer, was used for pre-column derivatization (OPA derivatization) using o-phthalaldehyde, as known from amino acid analysis. To detect the OPA derivatives of L-cysteine sulfinic acid, L-cysteine sulfonic acid, taurine, and taurine, the HPLC system was equipped with a fluorescence detector. The detector was set to an excitation wavelength of 330 nm and an emission wavelength of 450 nm. Also used was a device from Thermo Scientific... TM Accucore TMThe aQ column, 100 mm in length, 4.6 mm in inner diameter, and 2.6 μm in particle size, was thermally equilibrated at 40 °C in a column oven.
[0175] Eluent A: 25mM sodium phosphate, pH 6.0
[0176] Eluent B: Methanol
[0177] Separation was performed in gradient mode: at a flow rate of 0.5 ml / min, 10% eluent B to 60% eluent B over 0–25 minutes, followed by 60% eluent B to 100% eluent B over 2 minutes, and then 100% eluent B for another 2 minutes. Retention time of L-cysteine: 3.2 minutes. Retention time of L-cysteine sulfinic acid: 4.1 minutes. Retention time of taurine: 14.8 minutes. Retention time of taurine: 15.7 minutes.
[0178] Example 2: Oxidation of taurine and cysteine by glucose oxidase (GOX)
[0179] A) Oxidize cysteine sulfinic acid to cysteine sulfonic acid using GOX:
[0180] The reaction was studied in two parallel batches (i.e., with and without GOX). 12 mg of L-cysteine sulfinic acid monohydrate (Sigma-Aldrich) was weighed into each of two 100 mL Erlenmeyer flasks; it was dissolved in 9.5 mL of 100 mM sodium acetate at pH 5.5, and 0.5 mL of 200 g / L glucose solution in the same buffer was added. To initiate the reaction, 50 μl of a commercially available solution of GOX from Aspergillus niger (Sigma-Aldrich) in 100 mM sodium acetate at pH 5.5 was added to one batch. According to the manufacturer, the GOX activity in this batch was 5 U / mL. The batch without GOX (control batch) was treated with 50 μl of 100 mM sodium acetate at pH 5.5. Each batch was shaken at 30 °C and 140 rpm (Infors incubator shaker). At the start of the reaction and 5 hours after the start of the reaction, 1 ml was taken from each batch, incubated at 80°C for 5 minutes, and centrifuged at 13,000 rpm for 5 minutes (Heraeus). TM Fresco TM 21. Centrifuge), and the supernatant was analyzed by HPLC as described above.
[0181] The contents of L-cysteine sulfinic acid and L-cysteine sulfonic acid in the batches using GOX and the batches not using GOX at the start (0 hours) and after a 5-hour reaction time are summarized in Table 3.
[0182] Table 3: Time-varying process of L-cysteine sulfinic acid to L-cysteine sulfonic acid via GOX in the presence of glucose.
[0183]
[0184] B) Oxidize taurine with GOX to taurine:
[0185] The reaction was studied in two parallel batches (i.e., with and without GOX). 12 mg of taurine (Sigma-Aldrich) was weighed into each of two 100 mL Erlenmeyer flasks; it was dissolved in 9.5 mL of 100 mM sodium acetate at pH 5.5, and 0.5 mL of 200 g / L glucose solution in the same buffer was added. To initiate the reaction, 50 μL of a commercially available solution of GOX from Aspergillus niger (Sigma-Aldrich) in 100 mM sodium acetate at pH 5.5 was added to one batch. According to the manufacturer, the GOX activity in this batch was 5 U / mL. The batch without GOX (control batch) was treated with 50 μL of 100 mM sodium acetate at pH 5.5. Each batch was shaken at 30 °C and 140 rpm (Infors incubator shaker). At the start of the reaction and 5 hours after the start of the reaction, 1 ml was taken from each batch, incubated at 80°C for 5 minutes, and centrifuged at 13,000 rpm for 5 minutes (Heraeus). TM Fresco TM 21. Centrifuge), and the supernatant was analyzed by HPLC as described above.
[0186] The contents of taurine and taurine in batches using GOX and batches not using GOX at the start (0 hours) and after a 5-hour reaction time are summarized in Table 4.
[0187] Table 4: Time-varying process of taurine oxidation to taurine via GOX in the presence of glucose.
[0188]
[0189] Example 3: Preparative oxidation of taurine to taurine using GOX:
[0190] The reaction was studied in two parallel batches, i.e., using different doses of the enzyme GOX, with the concentration of the taurine substrate undergoing oxidation at 20 g / L in each case.
[0191] In batch 1, 200 mg of taurine (Sigma-Aldrich) was weighed into a 100 ml Erlenmeyer flask, dissolved in 6.95 ml of 100 mM sodium acetate at pH 5.5, and 3 ml of 200 g / L glucose solution in the same buffer was added. To initiate the reaction, 50 μl of a commercially available solution of GOX from Aspergillus niger (Sigma-Aldrich) in 100 mM sodium acetate at pH 5.5 was added. According to the manufacturer's information regarding enzyme activity, the GOX activity in this batch was 5 U / ml.
[0192] In batch 2, 200 mg of taurine (Sigma-Aldrich) was weighed into a 100 ml Erlenmeyer flask, dissolved in 6.5 ml of 100 mM sodium acetate at pH 5.5, and 3 ml of 200 g / L glucose solution in the same buffer was added. To initiate the reaction, 500 μl of a commercially available solution of GOX from Aspergillus niger (Sigma-Aldrich) in 100 mM sodium acetate at pH 5.5 was added. According to the manufacturer's information regarding enzyme activity, the GOX activity in this batch was 50 U / ml.
[0193] Batch 1 and 2 were shaken at 30°C and 140 rpm (Infors incubator shaker). At 3, 6, and 24 hours after the start of the reaction, 1 ml aliquots of each batch were taken, incubated at 80°C for 5 minutes, and centrifuged at 13,000 rpm for 5 minutes (Heraeus). TM Fresco TM 21. The supernatant was analyzed by HPLC as described above using a centrifuge. The reaction process over time is summarized in Table 5.
[0194] Table 5: Time-varying process of taurine oxidation to taurine via GOX in the presence of glucose.
[0195]
[0196] Example 4: Production of taurine-producing strains *Escherichia coli* K12 W3110 x pCys-CDOrn-CSADhs and *Escherichia coli* K12 W3110-ppsA-MHI x pCys-CDOrn-CSADhs
[0197] Cysteine dioxygenase CDOrn:
[0198] The amino acid sequence of CDOrn, a cysteine dioxygenase from brown rats, is disclosed in the NCBI (National Center for Biotechnology Information) database under sequence ID: AAH70509.1. This amino acid sequence was used to obtain a codon-optimized DNA sequence for expression in *E. coli* (using the publicly available Eurofins Genomics GENEius software), which was synthetically generated (Eurofins Genomics). This DNA sequence, named CDOrn, is disclosed in SEQ ID NO:1 and encodes a protein having the amino acid sequence from SEQ ID NO:2.
[0199] Cysteine sulfinate decarboxylase (CSADhs):
[0200] The amino acid sequence of CSADhs, a cysteine decarboxylase from Homo sapiens, is disclosed in the NCBI (National Center for Biotechnology Information) database under sequence ID: XP_016861786.1. This amino acid sequence was used to obtain a codon-optimized DNA sequence for expression in *E. coli* (using the publicly available Eurofins Genomics GENEius software). The DNA sequence, named CSADhs, is disclosed in SEQ ID NO:3, nt 1 to 1509, and encodes a protein having the amino acid sequence from SEQ ID NO:4. The DNA sequence of the *E. coli* rrnB terminator (SEQ ID NO:3, nt 1510 to 1842) was used for coupling to nt 1509. The DNA sequence of the rrnB terminator is disclosed in Orosz et al., Eur. J. Biochem. (1991) 201:653-659. The DNA consisting of CSADhs cds and the rrnB terminator disclosed in SEQ ID NO:3 is synthetically produced (Eurofins Genomics) and named CSADhs-rrnB.
[0201] Production of the carrier pCys-CDOrn-CSADhs:
[0202] -carrier pCys( Figure 1This refers to plasmid pACYC184-cysEX-GAPDH-ORF306-serA317, a derivative of plasmid pACYC184-cysEX-GAPDH-ORF306 disclosed in EP 0885 962 B1. Plasmid pACYC184-cysEX-GAPDH-ORF306 contains not only the origin of replication and tetracycline resistance gene (parental vector pACYC184), but also the cysEX allele (encoding a serine O-acetyltransferase with feedback inhibition of reduced cysteine) and the efflux gene ydeD (ORF306) (whose expression is controlled by the constitutive GAPDH promoter).
[0203] To obtain pACYC184-cysEX-GAPDH-ORF306-serA317, a serA317 gene fragment (referred to as “NSD:317”) encoding the N-terminal 317 amino acids of the *E. coli* SerA protein and disclosed in Bell et al., Eur. J. Biochem. (2002) 269:4176-4184 was cloned into pACYC184-cysEX-GAPDH-ORF306 following the ydeD(ORF306) efflux gene. SerA317 encodes a serine feedback resistance variant of 3-phosphoglycerate dehydrogenase. SerA317 expression is controlled by the serA promoter.
[0204] Due to deregulated biosynthesis, pCys-transformed E. coli cells produce cysteine, the starting product of derivatives cysteine sulfinic acid and taurine.
[0205] -carrier pCys-CDOrn-CSADhs( Figure 2 ):
[0206] pCys was cleaved using ScaI and PpuMI. Preparative agarose gel electrophoresis was performed. The GelExtraction kit (Qiagen) separates the 6.1kb vector fragment released from it.
[0207] Using primers cdorn-1f (SEQ ID NO:5) and csadhs-2r (SEQ ID NO:6), PCR was performed via (“Phusion”). TM High Fidelity DNA polymerase, Thermo Scientific TM CDOrn DNA was amplified from the synthesized DNA SEQ ID NO:1 (CDOrn) and isolated as a 0.6kb fragment.
[0208] Primer cdorn-1f contains 28 nts (nts 1 to 28 in SEQ ID NO:5) starting from the 5' end, overlapping the 3' end of the 6.1 kb pCys ScaI / PpuMI vector fragment obtained by ScaI digestion, ribosome binding sites (RBS) (nts 31 to 36 in SEQ ID NO:5), and the first 22 nts of CDOrn cds (nts 44 to 65 in SEQ ID NO:5).
[0209] Primer csadhs-2r contains 22 nts (SEQ ID NO:6, nts 1 to 22) that overlap with the origin of CSADhs cds in reverse complementary form starting from the 5' end, followed by a ribosome binding site (SEQ ID NO:6, nts 30 to 35) and the last 20 nts of CDOrncds (SEQ ID NO:6, nts 38 to 57).
[0210] -CSADhs-rrnB DNA: PCR was performed using primers csadhs-3f (SEQ ID NO:7) and glf-2r (SEQ ID NO:8) via Phusion. TM High Fidelity DNA polymerase, Thermo Scientific TM DNA fragments were amplified from the synthesized DNA SEQ ID NO:3 (CSADhs-rrnB) and isolated as 1.8kb fragments.
[0211] Primer csadhs-3f contains 20 nts (nts 1 to 20 in SEQ ID NO:7) starting from the 5' end and overlapping with the 3' end of CDOrn cds, ribosome binding sites (nts 23 to 28 in SEQ ID NO:7), and the first 22 nts of CDOrn cds (nts 36 to 57 in SEQ ID NO 7).
[0212] Primer glf-2r contains 33 nts (nts 1 to 33 in SEQ ID NO:8) that overlap with the 5' end of the 6.1 kbp Cys ScaI / PpuMI vector fragment obtained by PpuMI digestion in a reverse complementary manner starting from the 5' end, followed by the last 22 nts of the rrnB terminator (nts 34 to 55 in SEQ ID NO:8).
[0213] - Carrier pCys-CDOrn-CSADhs: Use according to the manufacturer's instructions. The cloning kit (NEB New England Biolabs) ligated a 6.1kb pCys ScaI / PpuMI vector fragment, a 0.6kb CDOrn PCR product (CDOrn DNA), and a 1.8kb CSADhs-rrnB PCR product (CSADhs-rrnB DNA).
[0214] Then the conjugated mixture was used to transform E. coli. 10-beta cells (NEB New England Biolabs) were used to select clones from transformation on LBtet. LBtet contained 10 g / L of tryptone (Gibco). TM The solution contained 5 g / L yeast extract (BD Biosciences), 5 g / L NaCl, 15 g / L agar, and 15 mg / L tetracycline (Sigma-Aldrich). Single clones from the transformation were analyzed by culturing in LBtet liquid medium (10 g / L tryptone, 5 g / L yeast extract, 5 g / L NaCl, and 15 mg / L tetracycline) and isolating the vector from the cultured cell clumps. The correct 8.5 kb vector was named pCys-CDOrn-CSADhs (…). Figure 2 ).
[0215] - Escherichia coli W3110:
[0216] The strain used was Escherichia coli K12 W3110 (obtained from DSMZ:DeutscheSammlung von Mikroorganismen und Zellkulturen GmbH [German Collection of Microorganisms and Cell Cultures], strain number DSM 5911).
[0217] -Escherichia coli strain W3110-ppsA-MHI:
[0218] The strain used was *Escherichia coli* K12 W3110-ppsA-MHI. *Escherichia coli* K12W3110-ppsA-MHI is characterized by a mutant ppsA gene encoding a protein, ppsA-MHI (SEQ ID NO: 9), having the protein sequence from SEQ ID NO: 10 and enzymatic activity of PEP synthase (enzyme nomenclature EC 2.7.9.2 in the KEGG database). *Escherichia coli* K12W3110-ppsA-MHI was produced using a combination well known to those skilled in the art through Lambda-Red recombination and anti-selection screening for gene modification (see, for example, Sun et al., *Appl. Env. Microbiol.* (2008) 74:4241-4245). To replace the ppsA WT gene in *Escherichia coli* K12 W3110 with ppsA-MHI, the following steps were performed:
[0219] 1) Transform E. coli K12 W3110 with plasmid pKD46 ( Figure 3 The strain was published in the GenBank database (access number AY048746.1) and the strain Escherichia coli W3110 x pKD46 (ampicillin-selected) was isolated.
[0220] 2) From plasmid pKan-sacB ( Figure 4 In this process, primers pps-9f (SEQ ID NO:11, and...) are used. Figure 4 The site named "pr-f" binds to both pps-10r (SEQ ID NO:12, and...) and pps-10r (SEQ ID NO:12, and...). Figure 4 A 3.2 kb Kan-sacB cassette was isolated by PCR from a site designated "pr-r" (binding to the site). The plasmid pKan sacB contains an expression cassette of the kanamycin (Kan) resistance gene and the sacB gene encoding fructan sucrase. The *E. coli* kanamycin resistance gene (Kan) encoding aminoglycoside phosphotransferase is publicly available in the NCBI database under access number SH02_03400. The *Bacillus subtilis* sacB gene is publicly available in the NCBI database under access number 936413.
[0221] Primer pps-9f contains the first 30 nts of the ppsAWT gene (identical to SEQ ID NO:9, nts 1-30), and is linked to it... Figure 4 The 20 nt locus is named "pr-f". Primer pps-10r contains the last 30 nts of the ppsAWT gene in reverse complementary form (identical to SEQ ID NO:9, nts 2350 to 2379) and the associated 20 nt locus. Figure 4The 20nt locus is named "pr-r".
[0222] Escherichia coli W3110 x pKD46 was transformed with a 3.2kb Kan-sacB box, and kanamycin-resistant clones were isolated.
[0223] 4) The clones were inoculated onto LBSC plates (10 g / L tryptone, 5 g / L yeast extract, 7% sucrose, 1.5% agar, and 15 mg / L kanamycin). Clones with integrated sacB genes produced toxic fructans from sucrose, leading to growth inhibition (sucrose sensitivity). A kanamycin-resistant and sucrose-sensitive clone was selected and named W3110-ppsA::Kan-sacB x pKD466.
[0224] 5) W3110-ppsA::Kan-sacB x pKD46 was transformed with DNA from the ppsA MHI gene (SEQ ID NO:9, synthesized by Eurofins Genomics), and clones were selected on kanamycin-free LBS plates (10 g / L tryptone, 5 g / L yeast extract, 7% sucrose, 1.5% agar). Only clones that no longer contained the active sacB gene were able to grow on LBS plates. These clones were then inoculated onto LBkan plates (10 g / L tryptone, 5 g / L yeast extract, 5 g / L NaCl, 1.5% agar, 15 mg / L kanamycin) to select clones that also no longer contained the active Kan gene and whose growth was inhibited in the presence of kanamycin.
[0225] 6) Clones exhibiting positive growth in the presence of sucrose and negative growth in the presence of kanamycin were selected. The ppsA-MHI gene was isolated from the genomic DNA of these strains by PCR, and DNA sequencing (Eurofins Genomics) confirmed the integration of the ppsA-MHI gene with the DNA sequence disclosed in SEQ ID NO:9, thereby encoding a protein corresponding to the sequence from SEQ ID NO:10. The strain after removing plasmid pKD46 by culturing at 42°C was named *Escherichia coli* W3110-ppsA-MHI.
[0226] - Production strains: Plasmid DNA from the vector pCys-CDOrn-CSADhs was transformed into strains *E. coli* K12 W3110 and *E. coli* K12 W3110-ppsA-MHI. For comparison, *E. coli* K12 W3110 and *E. coli* K12 W3110-ppsA-MHI* were transformed with the vector pCys. Transformed strains were selected on LBtet. One clone was isolated from each case. The strains were named *E. coli* K12 W3110 x pCys-CDOrn-CSADhs and *E. coli* K12 W3110 x pCys, respectively, and by analogy, *E. coli* K12 W3110-ppsA-MHI x pCys-CDOrn-CSADhs and *E. coli* K12 W3110-ppsA-MHI x pCys. Escherichia coli K12 W3110x pCys-CDOrn-CSADhs and Escherichia coli K12 W3110-ppsA-MHI x pCys-CDOrn-CSADhs were used as production strains for the production of taurine.
[0227] Example 5: Production of taurine in shake flasks
[0228] Pre-cultures in LBtet liquid medium were produced from each of the following strains: Escherichia coli K12 W3110 x pCys-CDOrn-CSADhs, Escherichia coli K12W3110 x pCys, Escherichia coli K12 W3110-ppsA-MHI x pCys-CDOrn-CSADhs, and Escherichia coli K12 W3110-ppsA-MHI xpCys (incubated overnight at 37°C and 120 rpm).
[0229] Major culture: Transfer 0.5 ml of the pre-culture to a 300 ml Erlenmeyer flask (with baffle) containing 30 ml of SM1-Ac medium, which also contains 15 g / L glucose, 2 g / L Na2S2O3·5H2O, 0.1 g / L L-isoleucine, 0.1 g / L D,L-methionine, 0.1 g / L L-threonine, 5 mg / L vitamin B1 and 15 mg / L tetracycline.
[0230] The SM1-Ac medium consists of: 12 g / L K2HPO4, 3 g / L KH2PO4, 5 g / L ammonium acetate, 0.3 g / L MgSO4·7H2O, 0.015 g / L CaCl2·2H2O, 0.002 g / L FeSO4·7H2O, 1 g / L trisodium citrate dihydrate, 0.1 g / L NaCl, and 1 ml / L trace element solution.
[0231] The composition of the trace element solution is as follows: 0.15 g / L Na₂MoO₄·2H₂O, 2.5 g / L H₃BO₃, 0.7 g / L CoCl₂·6H₂O, 0.25 g / L CuSO₄·5H₂O, 1.6 g / L MnCl₂·4H₂O, and 0.3 g / L ZnSO₄·7H₂O.
[0232] The major culture was incubated for 24 hours at 30°C and 140 rpm in an incubator (Infors). After 24 hours, 1 ml of sample was taken and cultured using a sample from Thermo Scientific. TM Genesys TM 10S UV / Vis spectrophotometer for measuring cell density (OD) 600 / ml (optical density of the main culture, measured spectrophotometrically at 600 nm), and the contents of taurine and taurine were determined by HPLC. For Escherichia coli K12 W3110 x pCys-CDOrn-CSADhs (cell density OD of the culture) 600 The concentration of taurine in the culture supernatant was 157.3 mg / L, as determined by HPLC. The concentration of taurine in the culture supernatant was 52.8 mg / L. (5.3 mg / L)
[0233] For Escherichia coli K12 W3110-ppsA-MHI x pCys-CDOrn-CSADhs (cell density OD of culture) 600 The content of taurine in the culture supernatant was 1059.2 mg / L and the content of taurine was 304.1 mg / L, as determined by HPLC. (ml: 7.1 / ml).
[0234] For the two comparative strains of Escherichia coli K12 W3110 x pCys (cell density OD of the culture) 600 / ml: 6.1 / ml) and Escherichia coli K12 W3110-ppsA-MHI x pCys (cell density OD of culture) 600 Taurine and taurine were not detected in either of the samples (7.5 / ml).
[0235] Example 6: Oxidation of taurine from shake flask cultures to taurine
[0236] Each 10 ml batch of shake flask cultures from *E. coli* W3110 x pCys-CDOrn-CSADhs and *E. coli* W3110-ppsA-MHI xpCys-CDOrn-CSADhs (Example 5) was centrifuged at 4000 rpm for 10 minutes (Heraeus).TM 1.0R), and transferred 9.4 ml of each supernatant to a 100 ml Erlenmeyer flask, and adjusted the pH to 5.5 with 0.7 M NaOH. Add 0.5 ml of a 200 g / L glucose solution in H₂O (final concentration in the mixture 10 g / L) and 100 μl of a 1 U / μl stock solution of GOX from Aspergillus niger in 100 mM pH 5.5 sodium acetate (final concentration 10 U / ml), and incubate the batch (10 ml volume) at 30 °C and 140 rpm in an incubator (Infors). At the start of incubation and 2 hours after the start of incubation, a 1 ml aliquot of each batch was taken, incubated at 80 °C for 5 minutes, and centrifuged at 13,000 rpm for 5 minutes (Heraeus). TM Fresco TM 21 centrifuges were used, and the supernatant was analyzed by HPLC.
[0237] As shown in Table 6, the taurine present in the shake-flask culture (Example 5) – 157.3 mg / L for strain W3110 xpCys-CDOrn-CSADhs and 1059.2 mg / L for strain W3110-ppsA-MHI x pCys-CDOrn-CSADhs – was completely consumed, with taurine formed at concentrations of 212.8 mg / L and 1355.6 mg / L, respectively. The molar yields were determined taking into account the different molecular weights (109.2 g / mol for taurine and 125.2 g / mol for taurine). As shown in Table 6, for strain W3110 x pCys-CDOrn-CSADhs, the combined concentration of taurine (1.4 mM) and taurine (0.4 mM) at the start of the reaction was 1.8 mM. Two hours after the reaction started, the taurine concentration was 1.7 mM, and taurine was no longer detectable. The molar yield of taurine from the enzymatic oxidation of the taurine / taurine product mixture, i.e., based on the total input of taurine and taurine from the shake flask culture (1.4 + 0.4 = 1.8 mM), was 94.4%. For strain W3110-ppsA-MHI x pCys-CDOrn-CSADhs, at the start of the reaction, the combined concentration of taurine (9.7 mM) and taurine (2.4 mM) was 12.1 mM. Two hours after the reaction started, the taurine concentration was 10.8 mM, and taurine was no longer detectable. The molar yield of taurine from the enzymatic oxidation of the taurine / taurine product mixture, i.e., based on the total input of taurine and taurine from the shake flask culture (9.7 + 2.4 = 12.1 mM), was 89.3%.
[0238] Table 6: Oxidation of taurine in shake-flask cultures of *Escherichia coli* strains K12 W3110 xpCys-CDOrn-CSADhs and *Escherichia coli* strain K12 W3110-ppsA-MHI x pCys-CDOrn-CSADhs after 2 hours of GOX culture in the presence of glucose.
[0239] W3110 x pCys-CDOrn-CSADhs:
[0240]
[0241] W3110-ppsA-MHI x pCys-CDOrn-CSADhs:
[0242]
Claims
1. A method for enzymatically oxidizing sulfinic acid of the formula H2N-CH(R)-CH2-SO2H to sulfonic acid of the formula H2N-CH(R)-CH2-SO3H using the enzyme in the presence of an enzyme substrate, wherein the enzyme is selected from oxidases that produce H2O2; Its features are, The oxidase that produces H2O2 is either an alcohol oxidase or a glucose oxidase. The group R is selected from hydrogen or carboxyl (-COOH).
2. The method according to claim 1, characterized in that, The substrate present is a primary alcohol.
3. The method according to claim 1, characterized in that, The substrate present is glucose.
4. The method according to any one of claims 1 to 3, characterized in that, The sulfinic acid is an aminoalkyl sulfinic acid, and the sulfonic acid is an aminoalkyl sulfonic acid.
5. The method according to any one of claims 1 to 3, characterized in that, The concentration of the sulfinic acid in the batch is at least 1 g / L.
6. The method according to any one of claims 1 to 3, characterized in that, The sulfinic acid is 2-aminoethanesulfinic acid (taurine), and the sulfonic acid formed is 2-aminoethanesulfonic acid (taurine).
7. The method according to any one of claims 1 to 3, characterized in that, The sulfonic acid is separated from the reaction batch.
8. The method according to claim 6, characterized in that, The taurine mentioned is taurine produced by fermentation.
9. The method according to claim 8, characterized in that, Taurine is produced by bacteria, meaning it is produced using bacterial strains.
10. The method according to claim 9, characterized in that, The bacterial production strain is Escherichia coli (Escherichia coli) Escherichia coli ) strains of the species.
11. The method according to claim 9, characterized in that, The producing strain is a strain with a deregulated cysteine biosynthesis pathway.
12. The method according to claim 9, characterized in that, The production strain is a strain E. coli One of W3110 xpCys-CDOrn-CSADhs or W3110-ppsA-MHI x pCys-CDOrn-CSADhs.
13. The method according to any one of claims 1 to 3, characterized in that, The sulfinic acid is cysteine sulfinic acid, and the sulfonic acid formed is cysteine sulfonic acid.
14. The method according to any one of claims 1 to 3, characterized in that, Based on the total molar concentration of sulfinic acid of formula H2N-CH(R)-CH2-SO2H and sulfonic acid of formula H2N-CH(R)-CH2-SO3H used in the reaction, the molar yield of sulfonic acid of formula H2N-CH(R)-CH2-SO3H is at least 60%.
Citation Information
Patent Citations
Process for preparing o-acetylserine, l-cysteine and l-cysteine-related products
EP0858510B1
Microorganisms and process for the fermentative production of L-Cystein, L-Cystin, N-Acetyl-Serin or thiazolidin-derivates
EP0885962B1
Process for fermentative production of amino acids and amino acid derivatives of the phosphoglycerate family
EP1382684B1
3-Phosphoglycerate dehydrogenase variants whose inhibition by L-serine is reduced, and genes encoding them
EP1950287B1
Heterologous Expression of Taurine in Microorganisms
US20190062757A1
